Receiveable Turnover: An accounting measure used to quantify a firm's effectiveness in extending credit as well as collecting debts. Calculated as: Total Revenues / Accounts Receivable
Poseida Therapeutics, Inc. (PSTX) had Receiveable Turnover of 7.18 for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
$64.70M |
|
$-123.43M |
|
-- |
|
$64.70M |
|
$194.21M |
|
$-129.50M |
|
$6.18M |
|
$-123.32M |
|
$-123.32M |
|
$-123.43M |
|
$-123.43M |
|
$-123.43M |
|
$-123.43M |
|
$-129.50M |
|
$-131.47M |
|
90.19M |
|
90.19M |
|
$-1.37 |
|
$-1.37 |
|
| Balance Sheet Financials | |
$226.47M |
|
$19.05M |
|
$47.41M |
|
$273.88M |
|
$71.32M |
|
$58.59M |
|
$98.87M |
|
$170.18M |
|
$103.70M |
|
$98.15M |
|
$103.70M |
|
95.64M |
|
| Cash Flow Statement Financials | |
$-92.17M |
|
$39.13M |
|
$16.13M |
|
$81.38M |
|
$44.47M |
|
$-36.91M |
|
$23.13M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.18 |
|
-- |
|
-- |
|
0.36 |
|
0.56 |
|
100.00% |
|
-200.15% |
|
-200.15% |
|
-203.19% |
|
-190.60% |
|
-190.76% |
|
$-95.23M |
|
-- |
|
-- |
|
-- |
|
0.24 |
|
-- |
|
|
Receiveable Turnover |
7.18 |
50.83 |
|
-119.02% |
|
-125.75% |
|
-45.07% |
|
-76.05% |
|
$1.08 |
|
$-1.06 |
|
$-1.02 |
|